Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jul 1;58(7):1307-1308.
doi: 10.1093/rheumatology/kez020.

Successful treatment of refractory mechanic's hands with ustekinumab in a patient with the antisynthetase syndrome

Iago Pinal-Fernandez  1   2 , Christopher T Kroodsma  3 , Andrew L Mammen  1   2
Affiliations
Case Reports

Successful treatment of refractory mechanic's hands with ustekinumab in a patient with the antisynthetase syndrome

Iago Pinal-Fernandez et al. Rheumatology (Oxford). .
No abstract available

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Mechanic’s hands Mechanic’s hands before (a, b) and after (c, d) starting treatment with ustekinumab.
See this image and copyright information in PMC

References

    1. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA. et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford) 2017;56:999–1007. - PMC - PubMed
    1. Nestle FO, Kaplan DH, Barker J.. Psoriasis. N Engl J Med 2009;361:496–509. - PubMed
    1. Mii S, Kobayashi R, Nakano T. et al. A histopathologic study of mechanic’s hands associated with dermatomyositis: a report of five cases. Int J Dermatol 2009;48:1177–82. - PubMed
    1. Papp KA, Griffiths CE, Gordon K. et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168:844–54. - PubMed
    1. Feagan BG, Sandborn WJ, Gasink C. et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016;375:1946–60. - PubMed

Supplementary concepts